COMBINATORIAL BCL-2 FAMILY EXPRESSION IN ACUTE MYELOID LEUKEMIA STEM CELLS PREDICTS CLINICAL RESPONSE TO AZACITIDINE/VENETOCLAX

被引：0
|
作者：
Waclawiczek, A. [1 ,2 ]
Leppa, A. [1 ,2 ]
Renders, S. [1 ,2 ,3 ]
Stumpf, K. [1 ,2 ]
Reyneri, C. [1 ,2 ]
Betz, B. [1 ,2 ]
Janssen, M. [3 ]
Shahswar, R. [4 ]
Donato, E. [1 ,2 ]
Unglaub, J. M. [3 ]
Schlenk, R. F. [3 ]
Hundemer, M. [3 ]
Pabst, C. [3 ]
Heuser, M. [4 ]
Raffel, S. [3 ]
Mueller-Tidow, C. [3 ]
Sauer, T. . [3 ]
Trumpp, A. [1 ,2 ]
机构：
[1] German Canc Res Ctr, Heidelberg, Germany
[2] HiSTEM GmbH, Heidelberg, Germany
[3] Univ Hosp Heidelberg, Heidelberg, Germany
[4] Hannover Med Sch, Hannover, Germany
来源：
ANNALS OF HEMATOLOGY | 2023年 / 102卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
41
引用
收藏
页码：S45 / S45
页数：1
相关论文
共 50 条
  • [41] Dual Targeting of Mitochondrial Vulnerability Using Complex I Inhibitor Iacs-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in Pre-Clinical Acute Myeloid Leukemia (AML) Models
    Zhang, Qi
    Han, Lina
    Lodi, Alessia
    Weng, Connie
    Kuruvilla, Vinitha Mary
    Cavazos, Antonio
    Ma, Helen
    Maiti, Abhishek
    Tabe, Yoko
    Marszalek, Joseph R.
    Tiziani, Stefano
    Konopleva, Marina
    BLOOD, 2020, 136
  • [42] Clinical relevance of flow cytometric BCL-2 and CD95 expression in acute myeloid leukemia.
    Kutlay, S
    Beksac, M
    Dalva, K
    Ilhan, O
    Akan, H
    Koc, H
    Ozcan, M
    Konuk, N
    Uysal, A
    BLOOD, 1997, 90 (10) : 3709 - 3709
  • [43] Clinical efficacy and immune response of BCL-2 inhibitors combined with hypomethylating agents in the treatment of acute myeloid leukemia
    Peng, Xiaohuan
    Yu, Jianing
    Tang, Futian
    Li, Yanhong
    Bai, Jun
    Li, Lijuan
    Zhang, Liansheng
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [44] High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia
    Karakas, T
    Maurer, U
    Weidmann, E
    Miething, CC
    Hoelzer, D
    Bergmann, L
    ANNALS OF ONCOLOGY, 1998, 9 (02) : 159 - 165
  • [45] HIGH BCL-2 EXPRESSION IN ACUTE MYELOID-LEUKEMIA CELLS CORRELATES WITH CD34 POSITIVITY AND POOR CLINICAL OUTCOME
    LAURIA, F
    RASPADORI, D
    VENTURA, MA
    RONDELLI, D
    PEDERZOLI, A
    CIMARELLI, S
    TURA, S
    BLOOD, 1994, 84 (10) : A378 - A378
  • [46] A concise review of BCL-2 inhibition in acute myeloid leukemia
    Yogarajah, Meera
    Stone, Richard M.
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (02) : 145 - 154
  • [47] BCL-2 inhibition in acute myeloid leukemia: resistance and combinations
    Tatarata, Qi Zhang
    Wang, Zhe
    Konopleva, Marina
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (12) : 935 - 946
  • [48] Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
    Punnoose, Elizabeth A.
    Leverson, Joel D.
    Peale, Franklin
    Boghaert, Erwin R.
    Belmont, Lisa D.
    Tan, Nguyen
    Young, Amy
    Mitten, Michael
    Ingalla, Ellen
    Darbonne, Walter C.
    Oleksijew, Anatol
    Tapang, Paul
    Yue, Peng
    Oeh, Jason
    Lee, Leslie
    Maiga, Sophie
    Fairbrother, Wayne J.
    Amiot, Martine
    Souers, Andrew J.
    Sampath, Deepak
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) : 1132 - 1144
  • [49] Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition
    Sharma, Prashant
    Pollyea, Daniel A.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (04) : 256 - 264
  • [50] Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition
    Prashant Sharma
    Daniel A Pollyea
    Current Hematologic Malignancy Reports, 2018, 13 : 256 - 264
12345